Moderna (MRNA) FCF Margin (2018 - 2026)

Moderna (MRNA) has reported FCF Margin for 9 consecutive years, with 388.28% the latest figure, recorded in Q2 2026.

• On a quarterly basis, FCF Margin rose 26102.0% year-over-year to 388.28% in Q2 2026; TTM through Jun 2026 was 55.83%, a 5755.0% increase from a year earlier, with the FY2025 full-year figure at 106.22%, up 1908.0% from the prior year.
• FCF Margin was 388.28% for Q2 2026 at Moderna, down from 177.89% in the prior quarter.
• Over five years, FCF Margin peaked at 131.42% in Q4 2025 and troughed at 1068.52% in Q1 2025.
• A 5-year average of 223.15% and a median of 89.41% in 2024 frame the typical range for FCF Margin.
• Across the five-year window, FCF Margin slumped 63772 bps in 2024 and soared 89063 bps in 2026, its largest moves.
• Over 5 years, FCF Margin stood at 30.88% in 2022, then tumbled by 54 bps to 14.3% in 2023, then surged by 119 bps to 31.37% in 2024, then surged by 319 bps to 131.42% in 2025, then sank by 395 bps to 388.28% in 2026.
• The last three FCF Margin figures came in at 388.28% (Q2 2026), 177.89% (Q1 2026), and 131.42% (Q4 2025), per Business Quant data.